H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Caribou Biosciences (CRBU – Research Report) today and set a price target of $23.00. The company’s shares closed yesterday at $6.54.
Burns covers the Healthcare sector, focusing on stocks such as Replimune Group, GT Biopharma, and BioNTech SE. According to TipRanks, Burns has an average return of -29.4% and a 19.64% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Caribou Biosciences with a $23.60 average price target.
See the top stocks recommended by analysts >>
CRBU market cap is currently $527.1M and has a P/E ratio of -3.68.
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CRBU in relation to earlier this year. Most recently, in June 2023, Haurwitz Rachel E., the President & CEO of CRBU bought 10,000.00 shares for a total of $29,600.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies.
Read More on CRBU:
- Caribou Biosciences price target lowered to $23 from $25 at H.C. Wainwright
- Caribou Biosciences’ data in LBCL looks ‘solid,’ says Truist
- Caribou Biosciences 19.23M share Spot Secondary priced at $6.50
- Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering
- Caribou: Follow-up data from Antler trial suggest CB-010 tolerated in r/r B-NHL
